NYSEAMERICAN:OCXOncoCyte Stock Price, Forecast & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for OncoCyte.

OncoCyte is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for OncoCyte.

OncoCyte Corp (NYSEAMERICAN:OCX) issued its quarterly earnings results on Tuesday, May, 12th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.02. The biotechnology company had revenue of $0.02 million for the quarter. View OncoCyte's earnings history.

2 analysts have issued 1-year target prices for OncoCyte's stock. Their forecasts range from $7.00 to $7.75. On average, they expect OncoCyte's share price to reach $7.38 in the next twelve months. This suggests a possible upside of 180.4% from the stock's current price. View analysts' price targets for OncoCyte.

Media headlines about OCX stock have trended extremely positive recently, according to InfoTrie. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. OncoCyte earned a media sentiment score of 4.7 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutOncoCyte.

Some companies that are related to OncoCyte include Bellus Health (BLU), CEL-SCI (CVM), Oxford BioMedica (OXB), Cel-Sci (CVM), SIGA Technologies (SIGA), Paradigm Biopharmaceuticals (PAR), Biotest (BIO), Neptune Wellness Solutions (NEPT), Silence Therapeutics (SLN), TELIX Pharmaceutical (TLX), Starpharma (SPL), Medicenna Therapeutics (MDNA), ProMetic Life Sciences (PLI), IMV (IMV) and Emblem (EMC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include BioTime (BTX), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Geron (GERN), Anavex Life Sciences (AVXL), Novocure (NVCR), Amicus Therapeutics (FOLD), Genocea Biosciences (GNCA), Inovio Pharmaceuticals (INO) and Ovid Therapeutics (OVID).

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

OncoCyte's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.51%), State Street Corp (0.69%), P.A.W. Capital Corp (0.56%), Geode Capital Management LLC (0.52%), Phoenix Holdings Ltd. (0.39%) and Penbrook Management LLC (0.35%). Company insiders that own OncoCyte stock include Andrew Arno, Biotime Inc, Broadwood Partners, LP, Mitchell S Levine, Ronald Asbury Andrews and Thomas Alex Vetter. View institutional ownership trends for OncoCyte.

OCX stock was sold by a variety of institutional investors in the last quarter, including Mesirow Financial Investment Management Inc., Morgan Stanley, BlackRock Inc., UBS Group AG, and State Street Corp. View insider buying and selling activity for OncoCyte.

OCX stock was bought by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd., P.A.W. Capital Corp, Penbrook Management LLC, Nuveen Asset Management LLC, Perkins Capital Management Inc., Geode Capital Management LLC, Bank of New York Mellon Corp, and ETF Managers Group LLC. Company insiders that have bought OncoCyte stock in the last two years include Andrew Arno, Broadwood Partners, LP, Mitchell S Levine, Ronald Asbury Andrews, and Thomas Alex Vetter. View insider buying and selling activity for OncoCyte.

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OCX stock can currently be purchased for approximately $2.63.

OncoCyte has a market capitalization of $176.78 million. OncoCyte employs 12 workers across the globe.

The official website for OncoCyte is www.oncocyte.com.

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (510) 775-0515.